Evogene (EVGN) Q3 2026 Earnings Call Transcript

Source The Motley Fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Thursday, Nov. 19, 2026

CALL PARTICIPANTS

  • Chairman of the Board of Directors - Nir Nimrodi
  • President and CEO - Ofer Haviv
  • VP Finance - Polina Ravzin

TAKEAWAYS

  • Consolidated Cash and Deposits -- $9.2 million as of Sept. 30, 2026, compared to $13.0 million at the end of 2025.
  • Quarterly Cash Usage -- $2.4 million during the third quarter, which included a $500,000 payment for Directors' and Officers' insurance.
  • Third Quarter Revenue -- $0.1 million, a decrease from $0.3 million in the prior year due to the expiration of the license and collaboration agreement with Bayer in May 2026.
  • Nine-Month Revenue -- $0.8 million, representing a decrease from $3.2 million in 2025 caused primarily by lower seed sales from the Casterra subsidiary.
  • Casterra Revenue Comparison -- Significantly lower than the $2.0 million recorded in the first half of 2025, which included nonrecurring seed sales.
  • Quarterly Net Loss -- $2.9 million, compared to net income of $5.2 million in 2025, reflecting income recognized from the ICL transaction in the prior year.
  • Nine-Month Net Loss -- $10.5 million, versus $2.5 million in 2025, driven by decreased revenue and higher financing expenses.
  • Nine-Month Net Loss Per Share -- $0.75 from continuing operations, compared to a loss per share of $0.84 in the prior year period.
  • Quarterly R&D Expenses -- $1.5 million, an increase from $1.1 million in 2025 caused by $200,000 in nonrefundable grants that lowered comparative expenses in the prior year.
  • Nine-Month R&D Expenses -- $4.5 million, compared to $4.6 million in 2025, supporting internal drug discovery and AgPlenus fungicide programs.
  • Nine-Month S&M Expenses -- $0.9 million, representing a decrease from $1.1 million in 2025 due to reduced marketing expenditures at Casterra and AgPlenus.
  • Quarterly G&A Expenses -- $1.1 million, held flat year over year as cost reductions were offset by nonrecurring legal and transaction fees.
  • Nonrecurring Transaction and Legal Costs -- $300,000 during the third quarter, associated with warrant inducement and corporate governance matters.
  • Nine-Month Financing Expenses -- $1.6 million, compared to financing income of $900,000 in 2025, resulting from the accounting treatment and revaluation of warrants.
  • Warrant Inducement Expense -- $3.8 million recorded for the first nine months of 2026, associated with a transaction conducted in Feb. 2026.
  • Warrant Revaluation Income -- $2.3 million recorded for the first nine months of 2026, stemming from the revaluation of warrant liabilities as of Sept. 30, 2026.
  • Steroid-Refractory aGVHD Market -- Estimated at $500 million annually, representing a significant segment of the total $2 billion global graft-versus-host disease treatment market.
  • Acute Graft-Versus-Host Disease Mortality -- Mortality rates reach as high as 50% for patients who do not respond to initial steroid treatments.
  • Acute Graft-Versus-Host Disease Incidence -- 30% to 40% of transplant recipients develop the condition, which is characterized by donor immune cells attacking recipient tissues.
  • Septoria Market Opportunity -- 1.2 billion euros, reflecting historically high fungicide utilization in European wheat production.
  • Septoria Disease Reduction -- 75% reduction in disease severity compared to untreated controls in plant tissue assays, as observed with AgPlenus' compounds.
  • Fungal Pathogen Activity -- Activity identified against Septoria and other fungal pathogens, suggesting potential applications across a broader range of diseases.
  • Fungal Strain Resistance -- AgPlenus compounds demonstrated efficacy against Septoria strains that have developed resistance to existing DMI, SDHI, and Qol fungicides.
  • Lead Compound Potency -- 0.4 nanomolar to 7.4 nanomolar concentrations in binding assays, demonstrating high biological potency for the internal drug discovery program.
  • Loss from Discontinued Operations -- $500,000 for the first nine months, following the sale of MicroBoost AI for Ag and Lavie Bio assets to ICL in July 2025.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Haviv warned that the growing resistance of fungal pathogens to existing fungicides, specifically succinate dehydrogenase inhibitors (SDHIs), highlights the need for new modes of action in wheat production.
  • Haviv noted that mortality rates among patients with steroid-refractory acute graft-versus-host disease can reach as high as 50%.

SUMMARY

Evogene (NASDAQ:EVGN) reported a reduction in revenue for the third quarter and first nine months of 2026, primarily due to the expiration of a major collaboration agreement and lower subsidiary seed sales. Management stated that the company is focusing on developing proprietary small-molecule assets using its AI-driven platform, ChemPass AI, for pharmaceutical and agricultural applications. Financial results for the period were impacted by transaction costs related to warrant inducements and nonrecurring legal expenses. The company reported a consolidated cash balance of $9.2 million and a reduction in operating expenses across several subsidiaries.

  • CEO Haviv stated, "In just several months, utilizing ChemPass AI, we generated a diverse series of novel small molecules candidates featuring the diverse chemical scaffolds."
  • Biological evaluations demonstrated that identified molecules inhibit fungal protein targets and show activity against strains resistant to existing fungicides.
  • On the call, management stated it expects to enter preclinical trials for its aGVHD program by mid-2027.
  • Haviv indicated, "Initial discussions have revealed strong interest among potential partner in innovative Septoria solutions based on novel mode of action."
  • The license and collaboration agreement with Bayer concluded in May 2026, which impacted year-over-year revenue comparisons.

INDUSTRY GLOSSARY

  • ChemPass AI: Evogene's proprietary AI-driven discovery and development platform for small molecules.
  • aGVHD: Acute graft-versus-host disease, a complication occurring after stem cell transplants where donor cells attack the recipient.
  • Septoria: A significant fungal disease affecting wheat production, particularly in Europe.
  • SDHIs: Succinate dehydrogenase inhibitors, a class of fungicides facing growing resistance issues.
  • ADME: Absorption, distribution, metabolism, and excretion; parameters used in evaluating the suitability of drug candidates.
  • Warrant Inducement: A transaction designed to encourage warrant holders to exercise their warrants, often involving a reduction in the exercise price.
  • IND-enabling: Investigational New Drug application studies required before beginning clinical trials in humans.
  • MicroBoost AI for Ag: A computational platform for the discovery of microbial-based agricultural products, sold to ICL in 2025.
  • Biomica: An Evogene subsidiary focused on the development of microbiome-based therapeutics.
  • Lavie Bio: An Evogene subsidiary focused on agricultural biologicals.
  • DMI: DeMethylation Inhibitors, a common class of fungicides used to control fungal diseases.
  • Qol: Quinone outside Inhibitors, a class of fungicides used widely in agricultural crop protection.

Full Conference Call Transcript

Operator: Welcome to Evogene's Third Quarter 2026 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded on November 19, 2026. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Evogene Ltd. may from time to time make other statements regarding our own outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA and other securities laws as amended.

Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimate, intend and potential or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimate market sizes and milestones, pipeline, as well as our capabilities and technology. Such statements are based on the current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict that are not guarantees of future performance.

Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors many of which are beyond our control, including without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah, Iran and other regional terrorist group supported by Iran, and any destabilization in Israel, neighboring terrorists (sic) [ territories ] or the Middle East region and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnished with the Israel Securities Authority and the U.S.

Securities and Exchange Commission, including those factors under the heading Risk Factors. Except as required by applicable securities law, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or development or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering documents, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Such use should not be construed as an endorsement of our products or services. With us on the line will be Nir Nimrodi, Evogene's Chairman of the Board of Directors; Ofer Haviv, President and CEO of Evogene; and Polina Ravzin, VP Finance of Evogene. Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.

Ofer Haviv: Good morning, everyone, and thank you for joining Evogene's Third Quarter 2026 Analyst Call. We appreciate your continued interest in the company and the opportunity to update you on our progress. In the first part of today's call, I would like to focus on 2 of the company's internal development programs, which demonstrate our strategy of leveraging our AI-driven discovery and development platform, ChemPass AI, to create proprietary assets with significant commercial potential, fully owned and managed by Evogene. These activities are being pursued alongside the collaborative product discovery programs that the company is leading, which I have discussed in previous calls.

The first program is Evogene internal drug discovery program targeting acute graft-versus-host disease, or aGVHD, the second comprises AgPlenus fungicide discovery program targeting Septoria, which focus on developing solutions with novel biological modes of action. I would like to emphasize that beyond the significant value associated with creating proprietary assets with meaningful economic potential, the results from these 2 programs also clearly demonstrate the strength of our platform, ChemPass AI. Following my remarks, I will hand over the discussion to Ms. Polina Ravzin, the company's VP Finance, who will focus on an analysis of the company's financial results for the first 9 months of the year and the third quarter. We will then open the call for questions and answers.

Let's begin with Evogene's internal drug discovery program. In October this year, we announced acute GVHD as the target indication for our internal drug discovery program. Acute GVHD is a serious medical implications that can develop following hematopoietic stem cell transplant. The disease is characterized by an acute immune response in which immune cells from the donor attack the recipient tissues. The unmet medical need is particularly significant among patients who do not respond to initial steroid treatment. According to published data, acute GVHD affects approximately 30% to 40% of transplant recipients and mortality rates among patients with steroid refractory disease can reach as high as 50%.

Despite the severity of the disease, second-line treatment options remains limited with ruxolitinib currently being the only approved treatment in this setting. Considering this significant unmet medical need, we identified an opportunity to develop therapeutic approach based on small molecules designed to target a key biological pathway involved in the severe inflammatory response associated with the disease. In our view, the selection of this indication reflects a combination of a significant unmet medical need and the opportunity to apply ChemPass AI discovery capabilities in an area where a new and differentiated therapeutic approach could potentially be developed. One of the most significant aspects of our announcement was the progress we achieved within a relatively short period of time.

In just several months, utilizing ChemPass AI, we generated a diverse series of novel small molecules candidates featuring the diverse chemical scaffolds. These molecules are patentable and were designed with particularly synthetic feasibility in mind. The molecules tested to date demonstrate several important characteristics and the most important is the high biological potency reaching nanomolar concentrations. Additionally, they show predicted promising preliminary ADME and toxicology profiles, which are important parameters when evaluating the potential of a molecule to advance through the drug development process.

We see this as a significant advantage because our objective is not simply to identify a molecule that demonstrates biological activity, but rather to generate candidates with a combination of proprietaries that could support their advancement through the drug development process. Another important aspect of this program is the scientific and clinical guidance provided by 2 leading experts in the acute GVHD field: Dr. Corey Cutler of Dana-Farber Cancer Institute; and Professor Dr. Robert Zeiser of University Medical Center of Freiburg. Their involvement supports our biological target selections, our understanding of the disease mechanisms and the overall clinical development strategy.

Our ability to generate within a relatively short period, a series of novel molecules combining several desirable proprietaries provides an important indication of our platform's ability, ChemPass AI, to generate candidates with therapeutic potential. It is important to emphasize that we are still at an early discovery and development stage and further optimization, characterization and evaluations of these candidates will be required. Looking ahead, our focus is on generating novel molecular structures, synthesizing these molecules, identifying the most promising candidates and further optimizing the leading series as we work toward IND-enabling studies. Let us now move to our second program in the agriculture chemical sector through our subsidiary, AgPlenus.

Earlier this week, AgPlenus announced significant progress in 2 fungicide discovery programs targeting novel modes of action against Septoria, one of the most economically significant disease affecting wheat production, mainly in Europe. According to the published data, historically, more than 70% of fungicides used European wheat production has been directed towards controlling this disease, representing an estimated market opportunity of approximately EUR 1.2 billion. One of the key challenges in this market is the growing resistance of fungal pathogens to existing fungicides, particularly widely used fungicide classes such as SDHIs. This highlights the need for new solutions based on different mode of actions that could provide effective alternatives as existing treatments became less effective.

This is precisely the opportunity that AgPlenus discovery programs are designed to address. In this program, AgPlenus is focusing on 2 proteins that are essential for fungal survival and have not previously been exploited as targets for commercial fungicide development. These targets were identified using the company's proprietary computational model, TargetSelector, which incorporates biological validation systems to assess the essentiality of selected protein targets. Building on this work, AgPlenus leveraged its ChemPass AI For Ag platform to design and generate active molecules targeting both proteins. Biological evaluations have demonstrated promising results. The identified molecules not only inhibit their intended fungal protein targets, but also exhibit fungicide activity, including against Septoria's strains that have developed resistance to existing fungicides.

One particularly encouraging result is that some of the molecules tested on fungus-infected plant tissue demonstrated a 75% reduction in disease severity compared to the untreated control. Importantly, some of these biological findings have also been independently validated by an external research organization, providing additional confidence in the results and supporting the continued advancement of both programs. In addition to Septoria, our evaluations have identified activity against other fungal pathogens, suggesting potential applications across a broader range of fungal diseases and opportunities to expand the commercial potential of certain molecules. Overall, we believe this finding represents an important milestone in AgPlenus' fungicide discovery efforts.

They demonstrate the potential of our computational discovery capabilities to develop molecules with novel mode of action, addressing one of the major challenge in modern crop protection, the growing resistance of fungal pathogens to existing fungicides. Our next step will focus on molecular optimizations, expanded biological testing and advancing the most promising candidates to greenhouse and substantially field trials. Initial discussions have revealed strong interest among potential partner in innovative Septoria solutions based on novel mode of action. We look forward to exploring collaboration opportunities over the coming year to accelerate development and enhance the program's commercial potential. This slide presents the company's overall activity, including its collaborations portfolio, while today's discussion has focused specifically on our internal development programs.

I believe that the 2 programs we present today clearly demonstrate Evogene's strategy of building an independent pipeline of product candidates based on small molecules. On the pharmaceutical side, we are advancing an internal development therapeutic assets in an area of significant medical need, leveraging the molecular discovery capabilities of ChemPass AI. On the agriculture side, through AgPlenus, we are applying similar technological capabilities to develop innovative solutions addressing resistance as a major challenge in crop protection. In both cases, our objective is to translate the company's technological and scientific advantage into proprietary assets with significant commercial potential.

We believe that the progress presented today provide an important foundation for the continued development of these programs and for creating value for the company and its shareholders. I would now like to hand over the discussion to Ms. Polina Ravzin, the company's VP Finance, who will present Evogene's financial results for the third quarter of 2026. Polina, over to you.

Polina Ravzin: Thank you, Ofer. I will now walk you through Evogene's financial results for the first 9 months and the third quarter of 2026. I will start with our cash position. As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period. Revenues for the 9 months of 2026 totaled approximately $0.8 million compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million.

The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026. Research and development expenses, net of non-refundable grants for the 9 months of 2026 were approximately $4.5 million compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million.

For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to the labilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025 as well as the impact of fluctuation of the U.S. dollar shekel exchange rate between the periods. Sales and marketing expenses for the 9 months of 2026 were approximately $0.9 million compared to approximately $1.1 million in the corresponding period of 2025.

Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million compared to approximately $0.4 million in the third quarter of 2025, primarily due to the lower sales and marketing expenses at Casterra and AgPlenus. General and administrative expenses for the 9 months ended September 30, 2026, decreased slightly to approximately $3.1 million compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025.

The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly with transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to the corporate governance and the shareholders' matters. These costs totaled approximately $0.4 million and $0.3 million during the 9-month and the 3-month periods ended September 30, 2026, respectively. Financing expenses, net, for the 9 months of 2026 were approximately $1.6 million compared to the financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction.

As part of the February 2026 warrant inducement transaction, the company recorded financing expenses of approximately $3.8 million during the first 9 months of 2026. In addition, the company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176,000 compared to approximately $79,000 in the corresponding period of 2025, with no material change between the periods. Loss from discontinued operations, net, for the 9 months of 2026 was approximately $0.5 million compared to an income from discontinued operations, net, of approximately $4 million in the corresponding period of 2025.

For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million compared to income of approximately $7.6 million in the third quarter of the previous year. This amount primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of the Lavie Bio's assets as well as Evogene's MicroBoost AI for Ag to ICL in July 2025, and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expenses levels have decreased significantly.

Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025. Net loss for the 9 months ended September 30, 2026, was approximately $10.5 million compared to approximately $2.5 million in the corresponding period of 2025. The $8 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025.

For the third quarter of 2026, net loss was approximately $2.9 million compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025 as discussed above. This concludes my review of our financial results. I will now turn the call back over to the operator.

Operator: [Operator Instructions] The first question from Scott Henry, AGP. When would you expect to out-license or partner your pharmaceutical compounds? How does the time line from compound selection to clinic trials differ between pharma and agricultural compounds? Was there any movement between stages for the disclosed pipeline during third quarter of 2026?

Ofer Haviv: This is Ofer. Can you hear me?

Operator: Yes, Ofer. We can hear you.

Ofer Haviv: Yes. Thank you. So with respect to the first question, I think that our internal program that we discussed today in detail is nicely advanced. And we are just now in the stage where we start to receive the novel compounds from the synthesis, and we are planning to validate them here in Israel, but also in the lab of the professor that is part from our Advisory Board in this program. And we expect to be able to enter into preclinical trial probably during mid next year.

I think this will be the time that then we can start to approach pharma company with the results that we will gather until this point of time, and on the initial results that we start to receive from the preclinical trial. And since this area, there are not too many companies like Evogene focusing on. And in the other hand, there is a few pharma companies that's interesting in this type of product. I really hope to see high interest even though that it's still in the early, early stage, I think this will be an interesting point where the work that we conduct will be judged by a pharma company.

I think also the fact that we are using the 2 advisors in this specific program, which they are awarded leaders of opinion. I think this is very important in our efforts also to commercialize those compounds when we get to this specific point in time. The second part is what is the difference between time to -- between Ag and pharma. So I think the big difference is the confidence you have, when you enter into the regulatory phase, which in human, you start the stage very early in the process because you cannot validate your compounds on human without the FDA approval to even to start the validation.

While in Ag, you can start the validation on crop without any regulatory approval, except for research level, which this is not a major issue to receive this type of approval. So when you start to the full regulatory stage, actually, you know that you have a product because you've made most of the validation earlier. So from a time perspective, the gap is not huge, but the information you have when you enter into the more critical phase and more expensive phase in Ag, the level of confidence is much higher compared to human.

In a way, what we are planning to do in the program for Septoria that we discussed today, we are planning to start the validation of the leading compound on crop, maybe first at the greenhouse and later on in field trial probably next year, which this is something that I can't say that we are going to do in our pharma program, meaning to validate the compounds on human, which is the equivalent to what I just now said that we are going to validate in wheat in greenhouse and field trial.

The third part of the question is if there is -- if we are advancing in our pipeline, in the different collaboration that we engage and we disclosed in the past. So today, I prefer to focus on the internal program, the program that we are managing and funding 100% by ourselves. There are advancement in the program that we are conducting with collaboration. We are going to release the company presentation soon. Every quarter, we release an update presentation where we disclose the current status of our pipeline. So I think that the information will be there.

And I can say that almost every month, we get more and more results from our partners that strengths our confidence on the quality of our platform. And my planning is that in the next analyst call to focus a lot on the ongoing collaboration agreement and the product pipeline status. And I think that we will be -- and I hope that we all feel very good in the progress in this aspect as well.

Operator: [Operator Instructions] There are no further questions at this time. Mr. Haviv, would you like to make a concluding statement?

Ofer Haviv: Yes. Thank you. I would like to thank everybody for participating in this analyst call. Feel free to contact me if you have any additional questions. I'm always available, and I'm looking forward to continue to update you on the future progress of Evogene. Thank you very much.

Operator: Thank you. This concludes Evogene's Third Quarter 2026 Results Conference Call. Thank you for your participation. You may go ahead and disconnect.

Should you buy stock in Evogene right now?

Before you buy stock in Evogene, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Evogene wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*

Now, it’s worth noting Stock Advisor’s total average return is 792% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 19, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
9 hours ago
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
15 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
placeholder
Australian Dollar falls below 0.6700 as Unemployment Rate jumps to the highest level in five yearsThe AUD/USD pair tumbles to its lowest since January around 0.6695 during the early Asian session on Thursday. The Australian Dollar (AUD) faces some selling pressure against the US Dollar (USD) following weaker-than-expected Australian employment data.
Author  FXStreet
16 hours ago
The AUD/USD pair tumbles to its lowest since January around 0.6695 during the early Asian session on Thursday. The Australian Dollar (AUD) faces some selling pressure against the US Dollar (USD) following weaker-than-expected Australian employment data.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
Yesterday 10: 14
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
Author  TradingKey
Yesterday 08: 35
Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
goTop
quote